BD completes clinical trial for its wearable injector

11 Feb 2020

The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.

BD (Becton, Dickinson and Company) has completed a 50-subject human clinical trial with the BD Libertas Wearable Injector.

BD completes clinical trial for its wearable injector
The BD Libertas Wearable Injector.

The award-winning injector (the Good Design Award and the iF Award) is a subcutaneous drug delivery system, currently in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

The BD independently sponsored and conducted study was designed to evaluate the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity and patient acceptance. The results are expected to be announced early 2020.

The study represents the most recent in a series of over 50 BD conducted pre-clinical and clinical studies intended to measure the performance of the BD Libertas Wearable Injector, demonstrate feasibility of 2-10 mL biologic injections into subcutaneous tissue and characterize tissue response to large volume injections in human and animal subjects.

Commenting on the study, Peter Nolan, Worldwide President, BD Pharmaceutical Systems, said: “BD is committed to bringing value to our pharma partnerships, including providing them with independent BD sponsored and generated study data to accelerate combination product development. The recent study reflects BD’s continued investment in solutions to meet pharma’s needs by expanding the design space for biologics delivery.”

Read More

Related news

HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more 
AstraZeneca incredibly excited by lung cancer treatment trial

AstraZeneca "incredibly excited" by lung cancer treatment trial

13 Apr 2020

Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.

Read more 
German pharma companies are meeting the corona stress test

German pharma companies are meeting the corona "stress test"

7 Apr 2020

The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.

Read more 
World’s leading biobanks join a global network to advance personalized healthcare research

World’s leading biobanks join a global network to advance personalized healthcare research

6 Apr 2020

The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

Read more 
Servier strengthens its R&D pipeline with Symphogen acquisition

Servier strengthens its R&D pipeline with Symphogen acquisition

6 Apr 2020

Symphogen becomes the antibody center of excellence within Servier.

Read more